Coherus BioSciences Q4 2024 Adj. EPS $(0.28) Misses $(0.13) Estimate, Sales $54.144M Beat $47.270M Estimate

Benzinga · 5d ago
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.13) by 115.38 percent. This is a 54.84 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $54.144 million which beat the analyst consensus estimate of $47.270 million by 14.54 percent. This is a 40.84 percent decrease over sales of $91.524 million the same period last year.